TY - JOUR
TI - NEOADJUVANT CISPLATIN AND INTERFERON-ALPHA-2B IN THE TREATMENT AND ORGAN
PRESERVATION OF PENILE CARCINOMA
AU - MITROPOULOS, D
AU - DIMOPOULOS, MA
AU - KIROUDIVOULGARI, A
AU - ZERVAS, A
AU - and DIMOPOULOS, C
AU - LOGOTHETIS, CJ
JO - Asian Journal of Urology
PY - 1994
VL - 152
TODO - 4
SP - 1124-1126
PB - Lippincott, Williams & Wilkins
SN - 2214-3882
TODO - 10.1016/S0022-5347(17)32520-X
TODO - PENILE NEOPLASMS; INTERFERON-ALPHA; CISPLATIN; INTERFERON ALFA-2B
TODO - We investigated the antitumor activity and toxicity of cisplatin and
interferon-alpha 2B as the primary treatment of penile carcinoma. A
total of 13 consecutive patients with nonmetastatic histologically
confirmed invasive squamous cell carcinoma of the penis underwent
treatment consisting of 20 mg./m.(2) cisplatin intravenously and 5 x
10(6) mu./m.(2) interferon-alpha 2B subcutaneously daily for 5
consecutive days. An equivalent dose of interferon was then administered
subcutaneously every 2 days for 3 weeks and the regimen was repeated at
28-day intervals. Of 12 evaluable patients 9 responded: 4 achieved a
pathologically confirmed complete remission of 38+, 21+, 10 and 7 months
in duration (2 with relapse were treated with local therapy and remain
with no evidence of disease), and 5 achieved a partial response,
underwent surgical removal of residual disease and remained disease-free
for 14+ to 24+ months. The most significant toxicities were anemia in 5
patients and reversible renal impairment in 3 but no patient had
neutropenic fever or required platelet transfusion. We conclude that
primary treatment with cisplatin and interferon-alpha 2B induced
responses in 75% of 12 patients with penile carcinoma and allowed for a
less radical operation than originally scheduled. A larger number of
patients and longer followup will be required to confirm these
encouraging preliminary results.
ER -